Skip to main content
. 2020 May 20;9(1):1766192. doi: 10.1080/20013078.2020.1766192

Figure 1.

Figure 1.

Exosomal HSP70 as a potential cancer biomarker. (a) Expression of circulating HSP70 within exosomes or soluble in paired samples at different time points (n = 68), Wilcoxon’s test, p < 0.0001. (b) Capture of tumour-derived exosomes by BLI using the peptide aptamer A8 from metastatic (M, n = 18), non-metastatic patients (NM, n = 19) and healthy volunteers (HC, n = 14), one way ANOVA, p < 0.0001. Recombinant human HSP70 (rhHSP70) and PBS are used as controls. (c) Expression of HSP70 within HSP70 exosomes either in all cancer patients (n = 37) or in lung cancer (n = 20) or breast cancer patients (n = 17) and healthy volunteers (n = 14), student t-test and ANOVA, p < 0.05, mean ± SEM. (d) Immunohistochemical HSP70 staining within tumour biopsy slides. A semi-quantitative evaluation was performed by counting positive cells in 100 cells, from three randomly selected fields. A representative immunohistochemistry picture of HSP70 expression is shown. NM = Non-metastatic, M = Metastatic.